Evidence map›Paper›PMID 32538426›Full record

ArticleThe Biochemical journal2020

Selective inhibition of Rhizopus eumelanin biosynthesis by novel natural product scaffold-based designs caused significant inhibition of fungal pathogenesis.

Sameh S M Soliman, Rania Hamdy, Samia A Elseginy, Teclegiorgis Gebremariam, Alshaimaa M Hamoda, Mohamed Madkour, Thenmozhi Venkatachalam, Mai N Ershaid, Mohammad G Mohammad, Georgios Chamilos and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Efficient selective targeting ofRSC medicinal chemistry · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Fungal Melanin and the Mammalian Immune System.Journal of fungi (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Sameh S M Soliman *Research Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Rania Hamdy *Research Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Samia A ElseginyGreen Chemistry Department, Chemical Industries Research Division, National Research Center, PO Box 12622, Giza, Egypt.
Teclegiorgis GebremariamDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovations, Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA 90509, U.S.A.
Alshaimaa M HamodaResearch Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Mohamed MadkourResearch Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Thenmozhi VenkatachalamResearch Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Mai N ErshaidResearch Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Mohammad G MohammadResearch Institute for Medical and Health Sciences, University of Sharjah, PO Box 27272, Sharjah, UAE.
Georgios ChamilosDepartment of Medicine, University of Crete, Foundation for Research and Technology, 71300 Heraklion, Crete, Greece.
Ashraf S IbrahimDivision of Infectious Diseases, The Lundquist Institute for Biomedical Innovations, Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, CA 90509, U.S.A.
University of Sharjah · AEZagazig University · EGUCLA Medical Center · USUniversity of Bristol · GBUniversity of California, Los Angeles · USUniversity of Crete · GR

Funding

Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
Iron Uptake and Mucormycosis PathogenesisR56AI063503 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI IBRAHIM, ASHRAF S. · 2005 to 2005
$281k
NIAID NIH HHS R01 AI063503NIAID NIH HHS R56 AI063503
6 · The paper itself

Abstract

Melanin is a dark color pigment biosynthesized naturally in most living organisms. Fungal melanin is a major putative virulence factor of Mucorales fungi that allows intracellular persistence by inducing phagosome maturation arrest. Recently, it has been shown that the black pigments of Rhizopus delemar is of eumelanin type, that requires the involvement of tyrosinase (a copper-dependent enzyme) in its biosynthesis. Herein, we have developed a series of compounds (UOSC-1-14) to selectively target Rhizopus melanin and explored this mechanism therapeutically. The compounds were designed based on the scaffold of the natural product, cuminaldehyde, identified from plant sources and has been shown to develop non-selective inhibition of melanin production. While all synthesized compounds showed significant inhibition of Rhizopus melanin production and limited toxicity to mammalian cells, only four compounds (UOSC-1, 2, 13, and 14) were selected as promising candidates based on their selective inhibition to fungal melanin. The activity of compound UOSC-2 was comparable to the positive control kojic acid. The selected candidates showed significant inhibition of Rhizopus melanin but not human melanin by targeting the fungal tyrosinase, and with an IC50 that are 9 times lower than the reference standard, kojic acid. Furthermore, the produced white spores were phagocytized easily and cleared faster from the lungs of infected immunocompetent mice and from the human macrophages when compared with wild-type spores. Collectively, the results suggested that the newly designed derivatives, particularly UOSC-2 can serve as promising candidate to overcome persistence mechanisms of fungal melanin production and hence make them accessible to host defenses.

Indexed as

Biological ProductsEnzyme ActivationHumansMelaninsMolecular StructureMonophenol MonooxygenasePhagocytosisPyronesRhizopusStructure-Activity RelationshipBiological Productseumelaninkojic acidMelaninsMonophenol MonooxygenasePyronesfungal melaninhuman melanininhibitorsphagocytosisRhizopus delemartyrosinase

Identifiers

PMID32538426
PMCPMC8558502
OpenAlexW3034991950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.